MARKET

REGN

REGN

Regeneron Pharmaceuticals
NASDAQ
785.51
+18.88
+2.46%
After Hours: 783.90 -1.61 -0.21% 19:30 02/06 EST
OPEN
769.63
PREV CLOSE
766.63
HIGH
786.99
LOW
764.78
VOLUME
671.66K
TURNOVER
--
52 WEEK HIGH
821.11
52 WEEK LOW
475.17
MARKET CAP
82.56B
P/E (TTM)
18.94
1D
5D
1M
3M
1Y
5Y
1D
Regeneron Data On EYLEA HD Dosing Shapes Retinal Disease Outlook
Simply Wall St · 1d ago
S&P 500 Analyst Moves: REGN
NASDAQ · 1d ago
Regeneron Targets Early Myeloma: New Phase 3 Trial Pits Linvoseltamab Against Daratumumab
TipRanks · 1d ago
Regeneron’s REGN9533 Trial Completion Signals Quiet but Important Progress in Clot-Blocking Drugs
TipRanks · 1d ago
TrumpRx’s launch is hours away. Here’s why it may not lower drug prices for most Americans.
MarketWatch · 2d ago
Regeneron (REGN) Q1 2025 Earnings Call Transcript
The Motley Fool · 2d ago
Regeneron (REGN) Q2 2025 Earnings Call Transcript
The Motley Fool · 2d ago
Regeneron (REGN) Q4 2024 Earnings Call Transcript
The Motley Fool · 2d ago
More
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Webull offers Regeneron Pharmaceuticals Inc stock information, including NASDAQ: REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.